AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00969163
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal placebo gel for 6 weeks
Trial: NCT04178928
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
Trial: NCT01144416
Drug: Placebo for SCH 900962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall.
Trial: NCT01144416
Drug: Placebo for recFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
Trial: NCT00440492
Drug: PLA-695
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05620056
Drug: chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
Trial: NCT00124072
Drug: Simvastatin 20 mg daily
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg tablet once daily
Trial: NCT00124072
Drug: Simvastatin 80 mg daily
RxNorm normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg tablet once daily
Trial: NCT00124072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vitamin B12/folic acid tablet once daily
Trial: NCT00092820
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02108756
Drug: Panmeilu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
Trial: NCT01001767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04115774
Drug: bisphosphonates
RxNorm normalized name: Bisphosphonates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
Trial: NCT00873821
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
Trial: NCT00873821
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
Trial: NCT02732483
Drug: Endo-Clot(TM)
RxNorm normalized name: 2-acetoxy-1, 8-cineole, (+)-endo-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
Trial: NCT02452762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02637700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
Trial: NCT03253887
Drug: Ethanol-lock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
Trial: NCT01121380
Drug: 1021
RxNorm normalized name: BARRIER,SENSURA COLOPLAST #11021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1021
Trial: NCT01238692
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
Trial: NCT02902185
Drug: ART plus Chidamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
Trial: NCT02902185
Drug: ART plus Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
Trial: NCT01985581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01985581
Drug: Stimulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
Trial: NCT02338960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02981342
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02981342
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT01629368
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of RO4917523
Trial: NCT03502850
Drug: ASK120067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
Trial: NCT01614990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (Powerade®) daily for 7 days.
Trial: NCT04016376
Drug: PVB Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
Trial: NCT04016376
Drug: PECS-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
Trial: NCT04016376
Drug: Serratus
RxNorm normalized name: FUCUS SERRATUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
Trial: NCT02520388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04170088
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline used for comparision of efficacy of tranexamic acid
Trial: NCT01814865
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg PO OD x 2 weeks
Trial: NCT03897452
Drug: Fentanyl (5 microgram/ml) prediluted ampoules
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation).
Trial: NCT01510119
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03756298
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
Trial: NCT02245256
Drug: placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02410499
Drug: MLN1202 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN1202 placebo-matching solution for SC injection
Trial: NCT03506412
Drug: Entresto™ 49Mg-51 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
Trial: NCT02410499
Drug: MLN1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN1202 solution for SC injection
Trial: NCT02541071
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03068975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
Trial: NCT01382017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00076011
Drug: Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03533452
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection
Trial: NCT01227941
Drug: MK-4827 + pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
Trial: NCT01227941
Drug: MK-4827 + pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
Trial: NCT01928290
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01928290
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03282344
Drug: NKTR-214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
Trial: NCT03745638
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Trial: NCT00584532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Placebo Capsules taken orally every day.
Trial: NCT00626886
Drug: placebo collagen sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: collagen
Trial: NCT00006101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take placebo per day for 12 months
Trial: NCT01318031
Drug: Period 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
Trial: NCT01318031
Drug: Period 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
Trial: NCT02168010
Drug: Neurotropin
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic drug as positive control
Trial: NCT01308255
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
Trial: NCT02168010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank tablet as placebo.
Trial: NCT00620828
Drug: Ropivicaine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivicaine
Trial: NCT01428180
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
Trial: NCT01428180
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
Trial: NCT02864849
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02857478
Drug: BAY 987519, SPF 50, Y51-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
Trial: NCT02857478
Drug: BAY 987519, SPF 50, P04-147
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
Trial: NCT00732147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 micrograms given subcutaneously before each meal x 3.
Trial: NCT02674113
Drug: regional anesthesia placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
Trial: NCT00206947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
Trial: NCT03775824
Drug: MTX start
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
Trial: NCT02147873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00080834
Drug: DJ-927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01358357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-80 mg flexible dose
Trial: NCT01452607
Drug: SPI-1005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Ebselen oral capsules (SPI-1005), single dose
Trial: NCT01452607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg Ebselen oral capsules (SPI-1000), single dose
Trial: NCT02473354
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
Trial: NCT00976716
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily
Trial: NCT00763347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
Trial: NCT00694759
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule twice daily
Trial: NCT00923351
Drug: Tumor Purged/CD25 Depleted Lymphocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00974012
Drug: Depakote®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ER Tablet
Trial: NCT04357015
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
Trial: NCT01169701
Drug: Mycophenolic acid (MPA)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
Trial: NCT02655757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo,1 tablet per day for 12 months
Trial: NCT00153595
Drug: EWO1
RxNorm normalized name: Ethinyl Estradiol and Norgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00651014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
Trial: NCT04643587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl)
Trial: NCT01103609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet bd, stepwise increased
Trial: NCT01103609
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet bd, stepwise increased
Trial: NCT01536314
Drug: Placebo : lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
Trial: NCT03930446
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
Trial: NCT02291055
Drug: ADXS11-001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02291055
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00077103
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin IV over 5-10 minutes
Trial: NCT01290146
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
Trial: NCT01828892
Drug: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
Trial: NCT02567799
Drug: BIO 300 Oral Suspension
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
Trial: NCT03309358
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
Trial: NCT01541137
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
Trial: NCT01541137
Drug: parecoxib/ valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes